We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Berkshire Hathaway, Honeywell, Becton, Dickinson, NXP Semiconductors N.V., and Ecolab
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 23, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B - Free Report) , Honeywell International Inc. (HON - Free Report) , Becton, Dickinson and Co. (BDX - Free Report) , NXP Semiconductors N.V. (NXPI - Free Report) and Ecolab Inc. (ECL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, Honeywell and Becton, Dickinson
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Honeywell International Inc. and Becton, Dickinson and Co. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
Shares of Berkshire Hathaway have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+40.9% vs. +24.1%). The Zacks analyst believes that the company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions, as the just announced Alleghany transaction shows. A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company's financial flexibility. Continued insurance business growth fuels increase in float, drive earnings and generates maximum return on equity.
The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus. However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
Honeywell International shares have declined -7.5% over the past year against the Zacks Diversified Operations industry's decline of -4.0%. The Zacks analyst believes that weakness across the personal protective equipment business will adversely impact its near-term results. Honeywell has been dealing with high costs and expenses and supply-chain challenges, which might affect its margins and profitability. Also, high debt levels might raise its financial obligations and hurt profitability.
However, Honeywell is expected to benefit from strength in the warehouse and workflow solutions, UOP and advanced materials businesses. It is likely to gain from acquisitions made over time. Also, its ability to generate strong cash flows add to its strength. The company's commercial and operational excellence initiatives are likely to be favorable.
Shares of Becton, Dickinson have outperformed the Zacks Medical - Dental Supplies industry over the past six-month period (+5.4% vs. -2.7%). The Zacks analyst believes that the company's base revenue uptick and robust results by majority of its arms in first-quarter fiscal 2022 are impressive. Regulatory approvals and launches are encouraging. BD's strategic deals augurs well. A raised outlook for full-fiscal year is also promising.
A strong solvency position is an added plus. BD's fiscal first-quarter results were better than expected. Yet, year-over-year falls in both top and bottom lines are disappointing. Fall in BD Life Science arm and both geographical areas are worrying. Lower COVID-only testing revenues are discouraging. Contraction of both margins does not bode well. BD's operation in a highly consolidated medical technology industry is worrying.
Other noteworthy reports we are featuring today include NXP Semiconductors N.V. and Ecolab Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Berkshire Hathaway, Honeywell, Becton, Dickinson, NXP Semiconductors N.V., and Ecolab
For Immediate Release
Chicago, IL – March 23, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B - Free Report) , Honeywell International Inc. (HON - Free Report) , Becton, Dickinson and Co. (BDX - Free Report) , NXP Semiconductors N.V. (NXPI - Free Report) and Ecolab Inc. (ECL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, Honeywell and Becton, Dickinson
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Honeywell International Inc. and Becton, Dickinson and Co. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Berkshire Hathaway have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+40.9% vs. +24.1%). The Zacks analyst believes that the company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions, as the just announced Alleghany transaction shows. A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company's financial flexibility. Continued insurance business growth fuels increase in float, drive earnings and generates maximum return on equity.
The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus. However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
(You can read the full research report on Berkshire Hathaway here >>>)
Honeywell International shares have declined -7.5% over the past year against the Zacks Diversified Operations industry's decline of -4.0%. The Zacks analyst believes that weakness across the personal protective equipment business will adversely impact its near-term results. Honeywell has been dealing with high costs and expenses and supply-chain challenges, which might affect its margins and profitability. Also, high debt levels might raise its financial obligations and hurt profitability.
However, Honeywell is expected to benefit from strength in the warehouse and workflow solutions, UOP and advanced materials businesses. It is likely to gain from acquisitions made over time. Also, its ability to generate strong cash flows add to its strength. The company's commercial and operational excellence initiatives are likely to be favorable.
(You can read the full research report on Honeywell International here >>>)
Shares of Becton, Dickinson have outperformed the Zacks Medical - Dental Supplies industry over the past six-month period (+5.4% vs. -2.7%). The Zacks analyst believes that the company's base revenue uptick and robust results by majority of its arms in first-quarter fiscal 2022 are impressive. Regulatory approvals and launches are encouraging. BD's strategic deals augurs well. A raised outlook for full-fiscal year is also promising.
A strong solvency position is an added plus. BD's fiscal first-quarter results were better than expected. Yet, year-over-year falls in both top and bottom lines are disappointing. Fall in BD Life Science arm and both geographical areas are worrying. Lower COVID-only testing revenues are discouraging. Contraction of both margins does not bode well. BD's operation in a highly consolidated medical technology industry is worrying.
(You can read the full research report on Becton, Dickinson here >>>)
Other noteworthy reports we are featuring today include NXP Semiconductors N.V. and Ecolab Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.